147 related articles for article (PubMed ID: 27158141)
1. Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.
Clark DE; Waszkowycz B; Wong M; Lockey PM; Adalbert R; Gilley J; Clark J; Coleman MP
Bioorg Med Chem Lett; 2016 Jun; 26(12):2920-2926. PubMed ID: 27158141
[TBL] [Abstract][Full Text] [Related]
2. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
[TBL] [Abstract][Full Text] [Related]
4. Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
Zhang W; Zhang K; Yao Y; Liu Y; Ni Y; Liao C; Tu Z; Qiu Y; Wang D; Chen D; Qiang L; Li Z; Jiang S
Eur J Med Chem; 2021 Feb; 211():113022. PubMed ID: 33239261
[TBL] [Abstract][Full Text] [Related]
5. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W
Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455
[TBL] [Abstract][Full Text] [Related]
6. Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen.
Palacios DS; Meredith E; Kawanami T; Adams C; Chen X; Darsigny V; Geno E; Palermo M; Baird D; Boynton G; Busby SA; George EL; Guy C; Hewett J; Tierney L; Thigale S; Weihofen W; Wang L; White N; Yin M; Argikar UA
Bioorg Med Chem Lett; 2018 Feb; 28(3):365-370. PubMed ID: 29275937
[TBL] [Abstract][Full Text] [Related]
7. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S
J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875
[TBL] [Abstract][Full Text] [Related]
8. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X
Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma.
Yin C; Jia S; Yang X; Wu L
Eur J Med Chem; 2024 May; 271():116444. PubMed ID: 38691889
[TBL] [Abstract][Full Text] [Related]
10. Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase.
Chen W; Dong G; He S; Xu T; Wang X; Liu N; Zhang W; Miao C; Sheng C
Bioorg Med Chem Lett; 2016 Feb; 26(3):765-768. PubMed ID: 26755394
[TBL] [Abstract][Full Text] [Related]
11. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
[TBL] [Abstract][Full Text] [Related]
12. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
[TBL] [Abstract][Full Text] [Related]
13. Fragment-based discovery of a potent NAMPT inhibitor.
Korepanova A; Longenecker KL; Pratt SD; Panchal SC; Clark RF; Lake M; Gopalakrishnan SM; Raich D; Sun C; Petros AM
Bioorg Med Chem Lett; 2018 Feb; 28(3):437-440. PubMed ID: 29287958
[TBL] [Abstract][Full Text] [Related]
14. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase.
Xu TY; Zhang SL; Dong GQ; Liu XZ; Wang X; Lv XQ; Qian QJ; Zhang RY; Sheng CQ; Miao CY
Sci Rep; 2015 Jun; 5():10043. PubMed ID: 26040985
[TBL] [Abstract][Full Text] [Related]
15. Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Dragovich PS; Bair KW; Baumeister T; Ho YC; Liederer BM; Liu X; Liu Y; O'Brien T; Oeh J; Sampath D; Skelton N; Wang L; Wang W; Wu H; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X
Bioorg Med Chem Lett; 2013 Sep; 23(17):4875-85. PubMed ID: 23899614
[TBL] [Abstract][Full Text] [Related]
16. Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
Zak M; Yuen PW; Liu X; Patel S; Sampath D; Oeh J; Liederer BM; Wang W; O'Brien T; Xiao Y; Skelton N; Hua R; Sodhi J; Wang Y; Zhang L; Zhao G; Zheng X; Ho YC; Bair KW; Dragovich PS
J Med Chem; 2016 Sep; 59(18):8345-68. PubMed ID: 27541271
[TBL] [Abstract][Full Text] [Related]
17. Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.
Matheny CJ; Wei MC; Bassik MC; Donnelly AJ; Kampmann M; Iwasaki M; Piloto O; Solow-Cordero DE; Bouley DM; Rau R; Brown P; McManus MT; Weissman JS; Cleary ML
Chem Biol; 2013 Nov; 20(11):1352-63. PubMed ID: 24183972
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel NAMPT inhibitors based on pharmacophore modeling and virtual screening techniques.
Yi Q; Zhou L; Shao X; Wang T; Bao G; Shi H; Zhou S; Li X; Tian Y
Comb Chem High Throughput Screen; 2014; 17(10):868-78. PubMed ID: 25413783
[TBL] [Abstract][Full Text] [Related]
19. Design of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase.
Lu T; Chen F; Yao J; Bu Z; Kyani A; Liang B; Chen S; Zheng Y; Liang H; Neamati N; Liu Y
J Med Chem; 2024 May; 67(10):8099-8121. PubMed ID: 38722799
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT.
Wang X; Xu TY; Liu XZ; Zhang SL; Wang P; Li ZY; Guan YF; Wang SN; Dong GQ; Zhuo S; Le YY; Sheng CQ; Miao CY
Sci Rep; 2015 Jul; 5():12657. PubMed ID: 26227784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
